Sensus Healthcare, Inc - SRTS STOCK NEWS

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company focused on non-invasive treatments, will hold a conference call on November 3, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results. The call will include a business update and insights on recent and upcoming milestones. Interested participants can access the call via dial-in or through a live webcast. An archived replay will be available until December 3, 2022. Sensus specializes in superficial radiation therapy for treating non-melanoma skin cancers and keloids.

Sensus Healthcare announced the launch of its Silk™ hair removal system at the Fall Clinical Dermatology Conference in Las Vegas, running from October 20-23, 2022. This portable device features a 2000W diode laser with blended wavelengths, suitable for all skin types. The innovative system promises efficient energy distribution without disposable parts, reducing costs for both patients and practitioners. The Silk™ system is available in two modes: an 810nm single wavelength and a blend of four wavelengths for comprehensive treatment. CEO Joe Sardano emphasizes its efficacy and versatility.

On September 9, 2022, Sensus Healthcare (Nasdaq: SRTS) announced its participation in the H.C. Wainwright 24^th Annual Global Investment Conference, scheduled for September 12-14, 2022, in New York City. Management will deliver a company overview and conduct one-on-one meetings with investors. A webcast of the presentation will be accessible on-demand starting September 12, 2022, at 7:00 a.m. ET on Sensus Healthcare’s website. The company specializes in innovative, non-invasive treatments for various conditions, particularly using its proprietary superficial radiation therapy technology.

Sensus Healthcare (Nasdaq: SRTS) announced the appointment of Dr. Mohammad K. Khan to its Medical Advisory Board, expanding its expertise in non-invasive treatment for oncological and non-oncological conditions. Dr. Khan, a renowned radiation oncologist at Emory University, specializes in various cancers and aims to enhance Sensus's Superficial Radiation Therapy (SRT) offerings. CEO Joe Sardano expressed optimism about Dr. Khan's contribution to market development for their innovative medical devices. This appointment underscores Sensus's commitment to advancing patient care through expert guidance.

Sensus Healthcare (Nasdaq: SRTS) has upgraded its SRT-100 Vision™ system with new solid-state High-Frequency Ultrasound technology. This enhancement includes an ergonomic probe for improved handling, allowing visualization of all skin layers, crucial for skin lesion treatment. The system also features electronic medical record capabilities for accurate image capture. CEO Joe Sardano highlighted the increased productivity and resolution of the new system, which is available immediately. Existing customers can upgrade by contacting their sales representatives.

Sensus Healthcare, Inc. (SRTS) reported strong financial results for Q2 2022, achieving revenues of $12.1 million, a 124% increase from Q2 2021. The net income for the quarter was $3.5 million, or $0.21 per diluted share, a significant turnaround from a net loss of $(0.3) million in the previous year. Adjusted EBITDA reached $4.7 million, compared to $(0.1) million in 2021. The company ended the quarter with $33.7 million in cash. Sensus affirms expectations for full-year profitability and highlights strong interest in its new TransDermal Infusion System™.

Sensus Healthcare (Nasdaq: SRTS) has sold 10 Transdermal Infusion Systems™ to Hair Enhancement Centers (HEC) in Texas, aimed at non-invasive hair health treatments. The first two systems will be delivered in Q3 2022, followed by the rest in Q4. This system enables painless delivery of U.SK Under Skin's Skin Savers Hair™ serum deep into hair follicles, enhancing patient satisfaction and treatment results. HEC has rapidly expanded from 2 to 9 clinics in 2022, providing hair loss treatments to millions of affected Americans.

Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on August 4, 2022, at 4:30 p.m. ET to discuss its second-quarter 2022 financial results. The management will also provide a business update and details on recent and upcoming milestones. The call can be accessed via phone or live webcast. Following the call, a replay will be available until September 3, 2022. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, featuring proprietary low-energy X-ray technology known as superficial radiation therapy.

Sensus Healthcare, Inc. (Nasdaq: SRTS) has expanded its partnership with Colorado State University (CSU) by supplying a second SRT-100™ system for the study of superficial radiation therapy (SRT) in horses. This initiative takes place at CSU's Johnson Family Equine Hospital, aiming to investigate ophthalmic indications. With SRT showing promising results in earlier studies on other animals, the potential market for veterinary applications is significant, considering there are around 30,000 veterinary practices in the U.S. The CSU team hopes to publish their findings next year.